Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections. 

Biotechnology

Spero Therapeutics

Sath Shukla

Kristyn McCandless

Esther Rajavelu

Ed Sopp

Troy Lister

Timothy Keutzer

Thomas Parr

Susan Redican

Shekman Wong

Kathy Burke

Laura McGinn

Nivedita Bhatt

Ilia Terova

Akash Jain

Jamie Brady

Myriah Satterfield

Indu Lakhani

Kamal Hamed

Frank E. Thomas

Tregoning Prior

Scott Jackson

John C. Pottage

David Musselman

Jay Blackington

Cristina Larkin

The Regulatory Affairs and Legal team at Spero Therapeutics ensures that all novel antibacterial and rare disease product candidates comply with regulatory requirements and legal standards. They oversee regulatory submissions, monitor compliance with industry regulations, and provide legal guidance to support the company's efforts in advancing treatment approaches for bacterial infections.

Regulatory Affairs and Legal

Leadership Team

Directors Team

Clinical and Research Operations

Regulatory Affairs and Legal

About

Team members

Other teams at Spero Therapeutics

Leadership Team

Directors Team

Clinical and Research Operations